tetano
Editor, Senior Moderator
NPJ Vaccines. 2017 Sep 14;2:26. doi: 10.1038/s41541-017-0026-4. eCollection 2017.
[h=1]A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies.[/h] Nachbagauer R[SUP]1[/SUP], Liu WC[SUP]1[/SUP], Choi A[SUP]1,[/SUP][SUP]2[/SUP], Wohlbold TJ[SUP]1,[/SUP][SUP]2[/SUP], Atlas T[SUP]1[/SUP], Rajendran M[SUP]1[/SUP], Sol?rzano A[SUP]1[/SUP], Berlanda-Scorza F[SUP]3[/SUP], Garc?a-Sastre A[SUP]1,[/SUP][SUP]4,[/SUP][SUP]5[/SUP], Palese P[SUP]1,[/SUP][SUP]5[/SUP], Albrecht RA[SUP]#[/SUP][SUP]1,[/SUP][SUP]4[/SUP], Krammer F[SUP]#[/SUP][SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza viruses evade human adaptive immune responses due to continuing antigenic changes. This makes it necessary to re-formulate and re-administer current seasonal influenza vaccines on an annual basis. Our pan-influenza vaccination approach attempts to redirect antibody responses from the variable, immuno-dominant hemagglutinin head towards the conserved-but immuno-subdominant-hemagglutinin stalk. The strategy utilizes sequential immunization with chimeric hemagglutinin-based vaccines expressing exotic head domains, and a conserved hemagglutinin stalk. We compared a live-attenuated influenza virus prime followed by an inactivated split-virus boost to two doses of split-virus vaccines and assessed the impact of adjuvant on protection against challenge with pandemic H1N1 virus in ferrets. All tested immunization regimens successfully induced broadly cross-reactive antibody responses. The combined live-attenuated/split virus vaccination conferred superior protection against pandemic H1N1 infection compared to two doses of split-virus vaccination. Our data support advancement of this chimeric hemagglutinin-based vaccine approach to clinical trials in humans.
PMID: 29263881 PMCID: PMC5627297 DOI: 10.1038/s41541-017-0026-4
[h=1]A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies.[/h] Nachbagauer R[SUP]1[/SUP], Liu WC[SUP]1[/SUP], Choi A[SUP]1,[/SUP][SUP]2[/SUP], Wohlbold TJ[SUP]1,[/SUP][SUP]2[/SUP], Atlas T[SUP]1[/SUP], Rajendran M[SUP]1[/SUP], Sol?rzano A[SUP]1[/SUP], Berlanda-Scorza F[SUP]3[/SUP], Garc?a-Sastre A[SUP]1,[/SUP][SUP]4,[/SUP][SUP]5[/SUP], Palese P[SUP]1,[/SUP][SUP]5[/SUP], Albrecht RA[SUP]#[/SUP][SUP]1,[/SUP][SUP]4[/SUP], Krammer F[SUP]#[/SUP][SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Influenza viruses evade human adaptive immune responses due to continuing antigenic changes. This makes it necessary to re-formulate and re-administer current seasonal influenza vaccines on an annual basis. Our pan-influenza vaccination approach attempts to redirect antibody responses from the variable, immuno-dominant hemagglutinin head towards the conserved-but immuno-subdominant-hemagglutinin stalk. The strategy utilizes sequential immunization with chimeric hemagglutinin-based vaccines expressing exotic head domains, and a conserved hemagglutinin stalk. We compared a live-attenuated influenza virus prime followed by an inactivated split-virus boost to two doses of split-virus vaccines and assessed the impact of adjuvant on protection against challenge with pandemic H1N1 virus in ferrets. All tested immunization regimens successfully induced broadly cross-reactive antibody responses. The combined live-attenuated/split virus vaccination conferred superior protection against pandemic H1N1 infection compared to two doses of split-virus vaccination. Our data support advancement of this chimeric hemagglutinin-based vaccine approach to clinical trials in humans.
PMID: 29263881 PMCID: PMC5627297 DOI: 10.1038/s41541-017-0026-4